PMV Pharmaceuticals, Inc.
Formerly PJ Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. is listed today as PMV Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2017 | $74 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
PMV Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2017).
SEC Form D · Mar 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2017
That is all the official record says: PMV Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of PMV Pharmaceuticals, Inc. are on record.
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Boxer Asset Management Inc. | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Boxer Capital, LLC | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Euclidean Capital LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Greenland A LLC | Other | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Greenland FP LLC | Other | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Greenland NFP B Ltd. | Company | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Greenland NFP LLC | Other | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| InterWest Management Partners X, LLC | Fund or asset manager | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Interwest Partners X LP | Fund or asset manager | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MVA Investors, LLC | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Nextech V GP S.A R.L. | Company | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Nextech V Oncology S.C.S., SICAV-SIF | Person | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Capital GP V LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Genesis GP LLC | Other | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 9 investors.
Largest shareholders today
Institutions holding PMV Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- BML Capital Management, LLC$12 M9.70%
- Tang Capital Management LLC$12 M9.64%
- Samsara Biocapital, LLC$12 M9.59%
- Sio Capital Management, LLC$6 M4.81%
- Vanguard Capital Management LLC$5 M4.08%
- ADAR1 Capital Management, LLC$5 M3.58%
- Euclidean Capital LLC$4 M3.48%
- Two Sigma Investments, LP$4 M3.22%
- Adage Capital Partners GP, L.L.C.$4 M3.12%
- Acadian Asset Management LLC$4 M3.03%
- Boxer Capital Management, LLC$3 M2.71%
- Eversept Partners, LP$3 M2.60%
- Affinity Asset Advisors, LLC$3 M2.32%
- ArrowMark Colorado Holdings LLC$3 M2.24%
- Millennium Management LLC$2 M1.94%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Mack | Executive officer | Mar 2017 |
| Arnold Levine | Director | Mar 2017 |
| Arnold Oronsky | Director | Mar 2017 |
| David Mack | Director | Mar 2017 |
| Peter Thompson | Director | Mar 2017 |
| Steve Winick | Director | Mar 2017 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.